Summary
35 / 100 · Bulios Score
What speaks for it
- It passes 8 of the 9 points of the Piotroski financial health test.
- It has been profitable 5 years in a row.
What to watch
- Repaying its net debt would take 7.8 years of operating profit.
- Earnings per share fell by 22% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 2.5 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 44.1 USD for 1 USD of yearly profit. Over the last five years it was 16.6 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.9% a year over 5 years. Over the last 3 years it grew by 1.1% a year. For the next fiscal year analysts expect revenue to grow by 8.5%. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 7
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.